How SeqOIA and AURAGEN genomic sequencing affects cancer care pathways
Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie
This project tests whether genomic sequencing performed by the SeqOIA and AURAGEN platforms changes care and treatment recommendations for cancer patients referred for high‑throughput sequencing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3149 (estimated) |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 3 sites (Lyon and 2 other locations) |
| Trial ID | NCT07147465 on ClinicalTrials.gov |
What this trial studies
SONCO is an observational national cohort that collects clinical and molecular data from all cancer patients referred to the SeqOIA and AURAGEN sequencing platforms. It links molecular tumor board reports captured via digital tools (SPICE and HYGEN) with hospital medical records to track treatment recommendations and patient care trajectories before and after sequencing. The project captures operational and quality indicators such as turnaround time, quality of patient information, and measures of diagnostic and therapeutic impact. Results are intended to inform national guidelines and help plan the organization and resource needs for future genomic services across France.
Who should consider this trial
Good fit: Ideal candidates are cancer patients in France who were referred for high‑throughput genomic sequencing with upstream RCP validation since January 1, 2021 and who have consented to reuse of their medical and genomic data.
Not a fit: Patients who oppose reuse of their data, whose sequencing referral was not validated by the upstream RCP, or whose care is unlikely to be influenced by genomic findings may not receive benefit from this project.
Why it matters
Potential benefit: If successful, this work could help speed up and personalize treatment decisions and guide hospitals and policymakers in organizing genomic services.
How similar studies have performed: Previous genomic sequencing programs have shown clinical benefit for subsets of oncology patients, but combining platform performance and nationwide care‑pathway impact in a single cohort is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with cancer and referred for high-throughput sequencing * Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021. Consent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use. Exclusion Criteria: * Opposition to data reuse, unvalidated upstream RCP
Where this trial is running
Lyon and 2 other locations
- Centre Leon Berard — Lyon, France (Recruiting)
- APHP Hôtel Dieu URC Economie de la sante /URC ECO — Paris, France (Active_not_recruiting)
- HOPITAL AP-HP Cochin — Paris, France (Recruiting)
Study contacts
- Principal investigator: Isabelle DURAND-ZALESKI, Professor — Greater Paris University Hospitals
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.